Team

Dr. Matthew Witek is a board-certified radiation oncologist and professor with over a decade of expertise in advanced radiation therapy. After starting his career in biopharmaceutical quality assurance, he earned a Master’s degree in Clinical Pharmacology and Therapeutics before transitioning into radiation oncology.

A recognized thought leader in head and neck cancer treatment, Dr. Witek has extensive experience developing innovative protocols and conducting in-depth analyses for international cooperative groups and investigator-initiated trials. His leadership as proton center director at two major academic hospitals enabled him to lead multidisciplinary teams effectively. This diverse background allows him to guide Veriray’s team of expert radiation oncologists, biologists, physicists, and dosimetrists, solidifying the company as the first and only clinical research organization specializing in radiation therapy.

Leigh Howe brings extensive financial and operational expertise to Veriray, having served as CEO and President of the Maryland Proton Treatment Center for a decade. There, she successfully expanded market share and implemented cutting-edge technologies.

With over 40 years of experience in leading U.S. banks and private investment firms, Ms. Howe has specialized in healthcare lending and investment. Her deep financial acumen in the healthcare sector equips her to drive Veriray’s sustained growth and innovation.

Dr. Mandira Mehra is a double-board-certified physician with an academic appointment in radiation oncology. She also serves as Chief Medical Officer for p360, where she oversees the development of innovative products and services designed to advance the pharmaceutical industry.

Her expertise in radiation therapy and leadership within the biopharmaceutical sector uniquely position her to support Veriray’s mission of pioneering radiation therapy-based services tailored to clinical trials and drug development.